Hepatitis C

In this segment, Nancy Reau, MD, and Kimberly Brown, MD, discuss ongoing challenges with viral hepatitis elimination efforts and clinical shortcomings in screening.

The investigational antisense oligonucleotide met the primary endpoint for functional cure rate in the phase 3 B-Well 1 and B-Well 2 trials in chronic hepatitis B.

The Q4 recap for hepatology spotlights new AASLD guidelines, changes to CDC hepatitis B vaccination recommendations, and more.

Catch up on new infant hepatitis B vaccine recommendations, liver transplant guidelines, research on GLP-1 RAs, and more.

The hepatology year in review highlights FDA approvals, MASH therapies, viral hepatitis advances, cholestatic disease shifts, and evolving clinical guidance.

The hepatitis year in review covers FDA approvals, HBV and HDV breakthroughs, HCV label expansion, clinical guidelines, and vaccine policy changes.

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

The 8-3 APIC vote recommends individual-based decision-making for HBV vaccination in infants born to women who test negative for the virus.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

Data presented at AASLD 2025 hepatitis delta patients experience significant physical and emotional challenges, emphasizing the need for holistic care approaches and screening beyond risk-based recommendations.

New global data show limited progress toward WHO’s 2030 hepatitis C elimination goals, highlighting disparities in diagnosis and treatment access.

Integrating facilitated telemedicine into opioid treatment programs led to SVR, improved patient satisfaction, and long-term health gains 5 years post-cure.

The Q3 recap for hepatology spotlights key FDA news, the withdrawal of OCA for PBC, and notable hepatic research from the past few months.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

Check out expert perspectives and new research on hepatitis C, cirrhosis, and more in this July 2025 recap.

Study findings suggest significant sex disparities in liver complication risk among adult patients with cirrhosis, especially in the context of nonviral cirrhosis.

The unsaturated fats from vegetable oils reduce inflammation and influence organ metabolism, resulting in lowered ALT, AST, and TBIL indexes.

A multidisciplinary care program achieved a 95% cure rate with Sofosbuvir/Velpatasvir therapy.

Deming explains drivers of new infections, systemic barriers impeding progress, and the changes she believes are needed to aid elimination efforts.

Nearly 13 million people received DAA treatment in the last 10 years, representing 21% of the starting 62 million people with chronic HCV and 30% of the target population.

Female sex and recent pregnancy were independent risk factors for reduced likelihood of DAA prescription among people with HCV entering opioid use disorder treatment.

Study findings highlight the cost-effectiveness of more frequent HCV testing among people who inject drugs compared with no testing and less frequent testing.

Nontargeted screening identified more HCV infections than targeted screening, but both approaches led to minimal linkage to care and SVR12.

The first half of 2025 recap for hepatology spotlights FDA approvals, clinical trial updates, and the 1-year anniversary of resmetirom.

The Q2 recap for hepatology spotlights regulatory approvals, clinical trial updates, and the launch of HCPLive’s flagship hepatology podcast.